Turnstone Biologics (TSBX) Competitors

$0.68

+0.01 (+1.07%)

(As of 09:48 AM ET)

TSBX vs. AFMD, IMRX, GRTS, ALRN, CLDI, KRON, VHAQ, EGRX, LSB, and YS

Should you be buying Turnstone Biologics stock or one of its competitors? The main competitors of Turnstone Biologics include Affimed (AFMD), Immuneering (IMRX), Gritstone bio (GRTS), Aileron Therapeutics (ALRN), Calidi Biotherapeutics (CLDI), Kronos Bio (KRON), Viveon Health Acquisition (VHAQ), Eagle Pharmaceuticals (EGRX), Lakeshore Biopharma (LSB), and YS Biopharma (YS). These companies are all part of the "pharmaceutical products" industry.

Turnstone Biologics vs.

Affimed (NASDAQ:AFMD) and Turnstone Biologics (NASDAQ:TSBX) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, community ranking, analyst recommendations, risk, dividends, media sentiment and valuation.

: 30.8% of Affimed shares are owned by institutional investors. Comparatively, 52.5% of Turnstone Biologics shares are owned by institutional investors. 3.8% of Affimed shares are owned by insiders. Comparatively, 32.1% of Turnstone Biologics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
: Turnstone Biologics has a net margin of 0.00% compared to Affimed's net margin of -2,922.74%. Turnstone Biologics' return on equity of -85.18% beat Affimed's return on equity.
Company Net Margins Return on Equity Return on Assets
Affimed -2,922.74% -155.30% -92.65%
Turnstone Biologics N/A -85.18% -72.25%
: Affimed presently has a consensus price target of $32.50, suggesting a potential upside of 720.71%. Turnstone Biologics has a consensus price target of $6.88, suggesting a potential upside of 919.27%. Given Turnstone Biologics' higher possible upside, analysts clearly believe Turnstone Biologics is more favorable than Affimed.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Affimed
0 Sell rating(s)
0 Hold rating(s)

4 Buy rating(s)

0 Strong Buy rating(s)
3.00
Turnstone Biologics
0 Sell rating(s)

0 Hold rating(s)

2 Buy rating(s)

0 Strong Buy rating(s)
3.00
: In the previous week, Affimed had 1 more articles in the media than Turnstone Biologics. MarketBeat recorded 1 mentions for Affimed and 0 mentions for Turnstone Biologics. Affimed's average media sentiment score of 1.44 beat Turnstone Biologics' score of -1.00 indicating that Affimed is being referred to more favorably in the media.
Company Overall Sentiment
Affimed Positive
Turnstone Biologics Negative
: Affimed has a beta of 2.11, indicating that its share price is 111% more volatile than the S&P 500. Comparatively, Turnstone Biologics has a beta of 2.27, indicating that its share price is 127% more volatile than the S&P 500.
: Affimed received 431 more outperform votes than Turnstone Biologics when rated by MarketBeat users. Likewise, 70.16% of users gave Affimed an outperform vote while only 66.67% of users gave Turnstone Biologics an outperform vote.
Company Underperform Outperform
Affimed Outperform Votes
435
70.16%
Underperform Votes
185
29.84%
Turnstone Biologics Outperform Votes
4
66.67%
Underperform Votes
2
33.33%
: Turnstone Biologics has higher revenue and earnings than Affimed.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Affimed $2.68M 22.47 -$114.66M N/A N/A
Turnstone Biologics $19.31M 0.81 -$55.20M -$10.14 -0.07

Company	Net Margins	Return on Equity	Return on Assets
Affimed	-2,922.74%	-155.30%	-92.65%
Turnstone Biologics	N/A	-85.18%	-72.25%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Affimed	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Turnstone Biologics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Company	Overall Sentiment
Affimed	Positive
Turnstone Biologics	Negative

Company	Underperform	Outperform
Affimed	Outperform Votes 435 70.16%	Underperform Votes 185 29.84%
Turnstone Biologics	Outperform Votes 4 66.67%	Underperform Votes 2 33.33%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Affimed	$2.68M	22.47	-$114.66M	N/A	N/A
Turnstone Biologics	$19.31M	0.81	-$55.20M	-$10.14	-0.07

Summary

Turnstone Biologics beats Affimed on 9 of the 15 factors compared between the two stocks.

Ad Stansberry Research

New President Kamala warning

Financial nightmare coming after election In 2018, one independent research predicted Kamala Harris was on her way to becoming the president of the United States. "Frankly, she scares us to death… and she should scare you," they wrote.

Which is why you need to check out their newest Kamala prediction immediately.

Get Turnstone Biologics News Delivered to You Automatically

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TSBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TSBX vs. The Competition

Export to Excel

Metric	Turnstone Biologics	Biological Products Industry	Medical Sector	NASDAQ Exchange
Market Cap	$15.60M	$3.07B	$5.70B	$8.47B
Dividend Yield	N/A	1.95%	5.03%	4.06%
P/E Ratio	-0.07	18.86	118.08	18.96
Price / Sales	0.81	340.55	1,739.92	87.37
Price / Cash	N/A	153.30	37.44	31.48
Price / Book	0.16	3.98	4.95	4.56
Net Income	-$55.20M	-$44.34M	$115.13M	$225.32M
7 Day Performance	5.39%	2.45%	10.27%	5.54%
1 Month Performance	-12.40%	1.80%	10.12%	6.00%
1 Year Performance	-84.35%	17.13%	33.24%	13.84%

Turnstone Biologics Competitors List

Export to Excel

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AFMD Affimed	4.3652 of 5 stars 4.37 / 5 stars	$4.00 +3.4%	$32.50 +712.5%	-17.5%	$60.92M	$8.95M	0.00	200	Short Interest ↓ Positive News Gap Up
IMRX Immuneering	3.7537 of 5 stars 3.75 / 5 stars	$2.02 +41.3%	$12.60 +523.8%	-69.4%	$59.89M	$320,000.00	-1.08	60	Analyst Revision Gap Up High Trading Volume
GRTS Gritstone bio	1.6506 of 5 stars 1.65 / 5 stars	$0.55 +14.6%	$4.75 +762.7%	-54.7%	$59.78M	$496,000.00	-0.44	190	Gap Up
ALRN Aileron Therapeutics	2.1186 of 5 stars 2.12 / 5 stars	$2.74 -4.2%	$19.00 +593.4%	+86.5%	$59.38M	N/A	-0.86	9	Positive News Gap Down
CLDI Calidi Biotherapeutics	1.9324 of 5 stars 1.93 / 5 stars	$1.16 flat	$16.67 +1,336.8%	N/A	$59.07M	$50,000.00	0.00	38	Gap Up
KRON Kronos Bio	3.6517 of 5 stars 3.65 / 5 stars	$0.95 +1.1%	$4.13 +334.2%	-27.1%	$57.09M	$8.41M	-0.48	100	Short Interest ↑ News Coverage
VHAQ Viveon Health Acquisition	0 of 5 stars 0.00 / 5 stars	$10.00 flat	N/A	N/A	$56.56M	N/A	0.00	2	High Trading Volume
EGRX Eagle Pharmaceuticals	4.089 of 5 stars 4.09 / 5 stars	$4.31 +12.5%	N/A	-72.2%	$55.99M	$316.61M	3.65	100	Upcoming Earnings Analyst Forecast Gap Up
LSB Lakeshore Biopharma	0.946 of 5 stars 0.95 / 5 stars	$0.60 +15.4%	N/A	N/A	$55.74M	$80.82M	0.00	773	Upcoming Earnings Gap Up
YS YS Biopharma	0 of 5 stars 0.00 / 5 stars	$0.60 +15.4%	$5.25 +776.5%	-12.3%	$55.74M	$560.76M	0.00	773	Gap Up